Back to search

Article

Anlotinib plus Tislelizumab for Recurrent Metastatic Pancreas Ductal Adenocarcinoma with Germline BRCA2 Mutation: A Case and Literature Review

2023-11-14

Abstract excerpt

<h4>Purpose: </h4> While combined immunotherapy and anti-angiogenic therapy have demonstrated efficacy in renal cell carcinoma, non-small cell lung cancer, and hepatocellular carcinoma, the efficacy of first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with germline BRCA2 mutation remains unproven. Methods We described a BRCA2-mutated PDAC patient who presented with posterior cardiac metastasis eigh...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e3ffdc88-7585-5a2f-9175-7d7388642fea
DOI
10.21203/rs.3.rs-3568907/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Anlotinib plus Tislelizumab for Recurrent Metastatic Pancreas Ductal Adenocarcinoma with Germline BRCA2 Mutation: A Case and Literature ReviewDOI 10.21203/rs.3.rs-3568907/v1
Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?Semantic proximity
Targeted Therapy for BRAF V600E Positive Pancreatic Adenocarcinoma: Two Case Reports.Semantic proximity
Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.Semantic proximity
Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.Semantic proximity
Molecular Characterization of a Long Term Survivor Double Metastatic Non Small Sell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line TherapySemantic proximity
Long-term complete remission of two patients with synchronous liver metastasis from pancreatic cancer and underlying BRCA-2 mutation.Semantic proximity
Durable Response of Induction Sequential Chemotherapy Combined With Nimotuzumab and Consolidative Carbon Ion Radiotherapy With Non-V600 BRAF Mutation Locally Advanced Pancreatic CancerSemantic proximity
First Reported Advanced Pancreatic Cancer With Hyperprogression Treated With PD-1 Blockade combined with chemotherapy: A Case Report And Literature ReviewSemantic proximity
Remarkable response of BRAFV600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case reportSemantic proximity
Severe Rashes Associated With Immunotherapy and Gene Mutations in a Patient With Metastatic Pancreatic CancerSemantic proximity
Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma.Semantic proximity
Synergistic effects of anlotinib and DDP synergy in breast cancer treatment: inhibiting of cell growth and migration, and augmenting apoptosis and autophagy via modulation of the VEGF/JAK2/STAT3 axisSemantic proximity
Select a neighboring publication to make it the new centre.